Novartis is to invest $35m in stem cell therapy developer Gamida Cell in exchange for a 15% stake of the Israeli firm and an option to acquire the company.
Reports of Novartis's intentions towards Gamida Cell first surfaced in Israeli media during March, although Novartis declined to confirm its...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

